Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
This formulation combines BPC-157 and Thymosin Beta-4 (TB4) in a 1:1 ratio, each at 5mg per vial in lyophilized form. It is currently under investigation in preclinical models for its potential synergistic effects on tissue regeneration, inflammation modulation, and cellular repair. BPC-157 is studied for its role in angiogenesis and growth factor regulation, while TB4 supports actin remodeling and cell migration. Together, they are of interest in research settings focused on muscle, tendon, ligament, and epithelial recovery. This compound is provided strictly for laboratory research purposes and is not approved for human or veterinary use.
This formulation combines BPC-157 and Thymosin Beta-4 (TB4) in a 1:1 ratio, each at 5mg per vial in lyophilized form. It is currently under investigation in preclinical models for its potential synergistic effects on tissue regeneration, inflammation modulation, and cellular repair. BPC-157 is studied for its role in angiogenesis and growth factor regulation, while TB4 supports actin remodeling and cell migration. Together, they are of interest in research settings focused on muscle, tendon, ligament, and epithelial recovery. This compound is provided strictly for laboratory research purposes and is not approved for human or veterinary use.